facebook
twitter
rss
account
search
search
 

Key medical panel to decide whether naproxen has less heart risk

Feb. 10, 2014 at 3:53 PM   |   Comments

WASHINGTON, Feb. 10 (UPI) -- U.S. medical experts this week are considering whether pain-killers containing naproxen carry less heart risk than other anti-inflammatory drugs.

A Food and Drug Administration panel meeting Monday and Tuesday is expected to make a recommendation on whether naproxen, sold as Aleve by Bayer, may present little, if any, danger to the heart. Such a declaration could give naproxen a marketing edge over competing drugs, such as ibuprofen -- sold as Advil, Motrin and generic versions -- and the prescription-only Celebrex, the Wall Street Journal reported.

The drugs are used by millions of people for joint pain, arthritis, other aches and injuries.

While the advisory panel could recommend label changes that would benefit the marketing of Aleve, the Journal noted the FDA isn't required to adopt the panel's suggestions. While the committee will vote Tuesday, the FDA decision will come later.

© 2014 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.
Recommended UPI Stories
Featured UPI Collection
trending
Notable deaths of 2014 [PHOTOS]

Notable deaths of 2014 [PHOTOS]

Most Popular
1
Schizophrenia is actually eight disorders, not one disease Schizophrenia is actually eight disorders, not one disease
2
Study: too many kids taking antibiotics Study: too many kids taking antibiotics
3
NFL players have 30 percent chance of developing Alzheimer's or dementia NFL players have 30 percent chance of developing Alzheimer's or dementia
4
Morning exercise helps calm ADHD symptoms in children Morning exercise helps calm ADHD symptoms in children
5
Yoga guru BKS Iyengar dies at 95 Yoga guru BKS Iyengar dies at 95
Trending News
Video
x
Feedback